Skip to main content
. 2020 Aug 26;84(1):161–163. doi: 10.1016/j.jaad.2020.08.095

Fig 1.

Fig 1

Meta-estimate of respiratory tract infections from publications of US Food and Drug Administration–approved dosages of phase 3 pivotal trials adverse events tables (includes “upper respiratory tract infections,” “nasopharyngitis,” “rhinitis,” “rhinorrhea,” “pneumonia,” bronchitis,” “sinusitis,” “pharyngitis,” “flu syndrome,” and “cough”). CI, Confidence interval; REML, restricted maximum likelihood.